Are HIV-1 seropositive subjects submitted to one of the innumerable AZT randomized double-blind trials, definitively victims of cross and/or common resistance to all virostatics, even in combinations?
Mathé
G
G
D004311:Double-Blind Method; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000453:epidemiology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D015215:Zidovudine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D015215:Zidovudine